Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Free Cash Flow: 2019-2025

Historic Free Cash Flow for Revolution Medicines (RVMD) over the last 7 years, with Sep 2025 value amounting to -$210.7 million.

  • Revolution Medicines' Free Cash Flow fell 57.28% to -$210.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$777.1 million, marking a year-over-year decrease of 41.00%. This contributed to the annual value of -$567.7 million for FY2024, which is 58.45% down from last year.
  • Revolution Medicines' Free Cash Flow amounted to -$210.7 million in Q3 2025, which was up 8.09% from -$229.2 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Free Cash Flow ranged from a high of -$35.4 million in Q2 2021 and a low of -$229.2 million during Q2 2025.
  • Over the past 3 years, Revolution Medicines' median Free Cash Flow value was -$133.9 million (recorded in 2024), while the average stood at -$142.1 million.
  • Data for Revolution Medicines' Free Cash Flow shows a maximum YoY slumped of 155.23% (in 2024) over the last 5 years.
  • Quarterly analysis of 5 years shows Revolution Medicines' Free Cash Flow stood at -$40.4 million in 2021, then slumped by 59.87% to -$64.7 million in 2022, then tumbled by 90.03% to -$122.9 million in 2023, then decreased by 13.54% to -$139.5 million in 2024, then plummeted by 57.28% to -$210.7 million in 2025.
  • Its last three reported values are -$210.7 million in Q3 2025, -$229.2 million for Q2 2025, and -$197.7 million during Q1 2025.